Avid Bioservices Inc
NASDAQ:CDMO

Watchlist Manager
Avid Bioservices Inc Logo
Avid Bioservices Inc
NASDAQ:CDMO
Watchlist
Price: 12.3 USD 0.41% Market Closed
Market Cap: 786.7m USD
Have any thoughts about
Avid Bioservices Inc?
Write Note

Avid Bioservices Inc
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Avid Bioservices Inc
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Avid Bioservices Inc
NASDAQ:CDMO
Current Portion of Long-Term Debt
$1.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Current Portion of Long-Term Debt
$12.6B
CAGR 3-Years
24%
CAGR 5-Years
19%
CAGR 10-Years
89%
Gilead Sciences Inc
NASDAQ:GILD
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Current Portion of Long-Term Debt
$3.5B
CAGR 3-Years
-6%
CAGR 5-Years
12%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Avid Bioservices Inc
Glance View

Market Cap
784.6m USD
Industry
Biotechnology

Avid Bioservices, Inc. engages in the commercial manufacturing. The company is headquartered in Tustin, California and currently employs 252 full-time employees. The firm is focused on development and Current Good Manufacturing Practices (CGMP) manufacturing of biopharmaceutical products derived from mammalian cell culture. The firm provides a range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The Company’s services include CGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The firm also provides process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization.

CDMO Intrinsic Value
18.42 USD
Undervaluation 33%
Intrinsic Value
Price

See Also

What is Avid Bioservices Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
1.5m USD

Based on the financial report for Jul 31, 2024, Avid Bioservices Inc's Current Portion of Long-Term Debt amounts to 1.5m USD.

What is Avid Bioservices Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 1Y
194%

Over the last year, the Current Portion of Long-Term Debt growth was 194%.

Back to Top